Pasado, presente y futuro de la vacunación anti-idiotipo

Rodriguez-Calvillo, M. (Mercedes); Inoges, S. (Susana); Lopez-Diaz-de-Cerio, A. (Ascensión); Zabalegui, N. (Natalia); Panizo, C. (Carlos); Hernandez, M. (Milagros); Perez-Calvo, J. (Javier); Prosper-Cardoso, F. (Felipe); Melero, I. (Ignacio); Sanchez-Ibarrola, A. (Alfonso); Rocha, E. (Eduardo); Bendandi, M. (Maurizio)

Palabras clave :

Inmunoterapia
Mieloma múltiple
Vacuna
Idiotipo
Linfoma

Fecha de publicación :

2004

Editorial :

Ediciones Universidad de Navarra

ISSN :

0556-6177

Cita:

Rodríguez Calvillo M, Inogés S, López Díaz de Cerio A, Zabalegui N, Panizo C, Hernández M, et al. Pasado, presente y futuro de la vacunación anti-idiotipo. Rev Med Univ Navarra. 2004 Jul-Sep;48(3):14-23.

Resumen

Cancer vaccines are conceived as therapeutic tools, in contrast to the prophylactic vaccines used to fight against infectious diseases. Among the most potent therapeutic vaccines, anti-idiotype vaccination is directed against the tumor idiotype, the only well-characterized tumor antigen displayed in neoplastic B-cells. Anti-idiotype vaccines have demonstrated clinical benefit against follicular lymphoma and are currently being evaluated in two different phase III clinical trials. Additional emerging strategies, which include the use of dendritic cells and the production of vaccines via molecular means will surely allow us to draw important conclusions concerning the treatment of cancer patients.

URI :

https://hdl.handle.net/10171/35407

Aparece en las colecciones:

DA - CIMA - Medicina regenerativa - Terapia celular - Artículos de Revista
DA - CUN - Hematología y Hemoterapia - Artículos de revista

Ficheros en este ítem: